BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schreuder TC, Gelderblom HC, Weegink CJ, Hamann D, Reesink HW, Devries JH, Hoekstra JB, Jansen PL. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int. 2008;28:39-46. [PMID: 18031478 DOI: 10.1111/j.1478-3231.2007.01610.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Li B, Zhao H, Wu P, Wu Q, Chen K, Mu Y. A systematic review and meta-analysis of endocrine-related adverse events associated with interferon. Front Endocrinol 2022;13:949003. [DOI: 10.3389/fendo.2022.949003] [Reference Citation Analysis]
2 Wang L, Chen K, Wang M, Lv Z, Gu W, Wang X, Ni Q, Mu Y. Characteristics of Interferon-Associated Diabetes Mellitus in Past 30 Years: A Review. Horm Metab Res 2022;54:145-52. [PMID: 35276739 DOI: 10.1055/a-1749-5716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Marroqui L, Perez-Serna AA, Babiloni-Chust I, Dos Santos RS. Type I interferons as key players in pancreatic β-cell dysfunction in type 1 diabetes. Int Rev Cell Mol Biol 2021;359:1-80. [PMID: 33832648 DOI: 10.1016/bs.ircmb.2021.02.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
4 Butt AA, Yan P, Aslam S, Shaikh OS, Abou-Samra AB. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES). Clin Infect Dis 2020;70:1153-60. [PMID: 30977808 DOI: 10.1093/cid/ciz304] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
5 Zhang JY, Cooper C, Doyle M. Association between hepatitis C antiviral treatment and diabetes mellitus: A case series. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada 2020;5:104-110. [DOI: 10.3138/jammi-2019-0007] [Reference Citation Analysis]
6 Muñoz Díaz HA, Lúquez Mindiola AJ, Gómez Aldana AJ. Fisiopatología de la hepatitis C y diabetes mellitus. Hacia la cura de dos epidemias en el siglo XXI. Rev Colomb Gastroenterol 2019;34:277-287. [DOI: 10.22516/25007440.322] [Reference Citation Analysis]
7 Laustsen A, Bak RO, Krapp C, Kjær L, Egedahl JH, Petersen CC, Pillai S, Tang HQ, Uldbjerg N, Porteus M, Roan NR, Nyegaard M, Denton PW, Jakobsen MR. Interferon priming is essential for human CD34+ cell-derived plasmacytoid dendritic cell maturation and function. Nat Commun 2018;9:3525. [PMID: 30166549 DOI: 10.1038/s41467-018-05816-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
8 Lombardi A, Tsomos E, Hammerstad SS, Tomer Y. Interferon alpha: The key trigger of type 1 diabetes. J Autoimmun. 2018;94:7-15. [PMID: 30115527 DOI: 10.1016/j.jaut.2018.08.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
9 Mandrup-Poulsen T. Granzyme A in the Pathogenesis of Type 1 Diabetes: The Yes and the No. Diabetes 2017;66:2937-9. [PMID: 29162734 DOI: 10.2337/dbi17-0037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
10 Lombardi A, Tomer Y. Interferon alpha impairs insulin production in human beta cells via endoplasmic reticulum stress. J Autoimmun 2017;80:48-55. [PMID: 28238527 DOI: 10.1016/j.jaut.2017.02.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 8.6] [Reference Citation Analysis]
11 Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne). 2015;6:134. [PMID: 26441826 DOI: 10.3389/fendo.2015.00134] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 8.4] [Reference Citation Analysis]
12 Chien CH, Lin CL, Hu CC, Chang JJ, Chien RN. Clearance of Hepatitis C Virus Improves Insulin Resistance During and After Peginterferon and Ribavirin Therapy. J Interferon Cytokine Res. 2015;35:981-989. [PMID: 26308911 DOI: 10.1089/jir.2014.0200] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
13 Zornitzki T, Malnick S, Lysyy L, Knobler H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol 2015; 21(1): 233-239 [PMID: 25574096 DOI: 10.3748/wjg.v21.i1.233] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
14 Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A, Fabiani S, Marchi S, Ferri C, Ferrannini E, Fallahi P. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes 2014; 5(5): 586-600 [PMID: 25317237 DOI: 10.4239/wjd.v5.i5.586] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 68] [Article Influence: 7.8] [Reference Citation Analysis]
15 Xia CQ, Peng R, Chernatynskaya AV, Yuan L, Carter C, Valentine J, Sobel E, Atkinson MA, Clare-Salzler MJ. Increased IFN-α-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-α production. J Immunol 2014;193:1024-34. [PMID: 24973447 DOI: 10.4049/jimmunol.1303230] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 5.8] [Reference Citation Analysis]
16 Cutolo M. Autoimmune polyendocrine syndromes. Autoimmun Rev. 2014;13:85-89. [PMID: 24055063 DOI: 10.1016/j.autrev.2013.07.006] [Cited by in Crossref: 85] [Cited by in F6Publishing: 91] [Article Influence: 9.4] [Reference Citation Analysis]
17 Molleston JP, Mellman W, Narkewicz MR, Balistreri WF, Gonzalez-Peralta RP, Jonas MM, Lobritto SJ, Mohan P, Murray KF, Njoku D, Rosenthal P, Barton BA, Talor MV, Cheng I, Schwarz KB, Haber BA; PEDS-C Clinical Research Network. Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2013;56:304-10. [PMID: 23439301 DOI: 10.1097/MPG.0b013e3182774cae] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
18 Khan R, Foster GR, Chowdhury TA. Managing diabetes in patients with chronic liver disease. Postgrad Med. 2012;124:130-137. [PMID: 22913901 DOI: 10.3810/pgm.2012.07.2574] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
19 Ranganathan R, Janarthanan K, Rajasekaran S. Onset of Type 1 Diabetes Mellitus During Pegylated-interferon Alfa and Ribavirin Therapy for Chronic Hepatitis C Virus Infection. J Clin Exp Hepatol 2012;2:86-7. [PMID: 25755410 DOI: 10.1016/S0973-6883(12)60089-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
20 Huang JF, Yu ML, Huang CF, Juo SH, Dai CY, Hsieh MY, Hou NJ, Yeh ML, Hsieh MH, Yang JF. The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. Liver Int. 2012;32:962-969. [PMID: 22356575 DOI: 10.1111/j.1478-3231.2012.02771.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
21 Oka R, Hiroi N, Shigemitsu R, Sue M, Oshima Y, Yoshida-Hiroi M. Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review. Clin Med Insights Endocrinol Diabetes. 2011;4:39-45. [PMID: 22879793 DOI: 10.4137/cmed.s7815] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
22 Nakamura K, Kawasaki E, Imagawa A, Awata T, Ikegami H, Uchigata Y, Kobayashi T, Shimada A, Nakanishi K, Makino H, Maruyama T, Hanafusa T; Research Committee on Type 1 Diabetes of the Japan Diabetes Society. Type 1 diabetes and interferon therapy: a nationwide survey in Japan. Diabetes Care 2011;34:2084-9. [PMID: 21775762 DOI: 10.2337/dc10-2274] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 4.8] [Reference Citation Analysis]
23 Huang JF, Dai CY, Yu ML, Huang CF, Huang CI, Yeh ML, Yang JF, Hou NJ, Hsiao PJ, Lin ZY. Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients. Liver Int. 2011;31:1155-1162. [PMID: 21745292 DOI: 10.1111/j.1478-3231.2011.02545.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
24 Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212-223. [PMID: 21386812 DOI: 10.1038/nrgastro.2011.21] [Cited by in Crossref: 99] [Cited by in F6Publishing: 104] [Article Influence: 9.0] [Reference Citation Analysis]
25 Muraishi K, Sasaki Y, Kato T, Inada C, Tajiri Y, Yamada K. Classification and characteristics of interferon-related diabetes mellitus in Japan: Interferon and diabetes mellitus. Hepatology Research 2011;41:184-8. [DOI: 10.1111/j.1872-034x.2010.00753.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
26 Kostandi I, Bahgat M, Zayed N, Rashed L. Assessment of Insulin Resistance and Insulin Growth Factor-1 in Egyptian Patients with Chronic Hepatitis C. OJEMD 2011;01:1-8. [DOI: 10.4236/ojemd.2011.11001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Eisenbarth GS, Buse JB. Type 1 Diabetes Mellitus. Williams Textbook of Endocrinology 2011. [DOI: 10.1016/b978-1-4377-0324-5.00032-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
28 Jasinski J, Eisenbarth GS. Primer on Immunoendocrinology. Immunoendocrinology: Scientific and Clinical Aspects 2011. [DOI: 10.1007/978-1-60327-478-4_1] [Reference Citation Analysis]
29 Pozzilli P, Strollo R, Napoli N. Drug-Induced Endocrine Autoimmunity. Immunoendocrinology: Scientific and Clinical Aspects 2011. [DOI: 10.1007/978-1-60327-478-4_10] [Reference Citation Analysis]
30 Michels A, Jeffrey J, Eisenbarth GS. Genetics of Type 1 Diabetes. Immunoendocrinology: Scientific and Clinical Aspects 2011. [DOI: 10.1007/978-1-60327-478-4_15] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Lee YN, Jeong SW, Lim JH, Ryu YS, Jeon SR, Kim SK, Jang JY, Kim YS, Kim BS, Roh MO. [Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C]. Korean J Hepatol. 2010;16:187-191. [PMID: 20606504 DOI: 10.3350/kjhep.2010.16.2.187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
32 Zipris D. Toll-like receptors and type 1 diabetes. Adv Exp Med Biol. 2010;654:585-610. [PMID: 20217515 DOI: 10.1007/978-90-481-3271-3_25] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
33 Eisenbarth GS. Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes. Diabetes 2010;59:759-74. [PMID: 20350969 DOI: 10.2337/db09-1855] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 6.2] [Reference Citation Analysis]
34 Michels AW, Eisenbarth GS. Immunologic endocrine disorders. J Allergy Clin Immunol 2010;125:S226-37. [PMID: 20176260 DOI: 10.1016/j.jaci.2009.09.053] [Cited by in Crossref: 60] [Cited by in F6Publishing: 68] [Article Influence: 5.0] [Reference Citation Analysis]
35 Carvalho-Filho RJ, Dalgard O. Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin. Pharmgenomics Pers Med 2010;3:1-13. [PMID: 23226039 DOI: 10.2147/pgpm.s4461] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Gonzalez G, Castro FP, Berho M, Petras R. Autoimmune enteropathy associated with cessation of interferon-alpha therapy in chronic hepatitis C. Dig Dis Sci 2010;55:1490-3. [PMID: 19639409 DOI: 10.1007/s10620-009-0877-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
37 Lo Y, Chang S, Sheng W, Hung C, Chang S. Association of pancreatic autoantibodies and human leukocyte antigen haplotypes with resolution of diabetes mellitus after therapy for hepatitis C virus infection in patients with HIV infection: case report and review of literature: . European Journal of Gastroenterology & Hepatology 2009;21:478-81. [DOI: 10.1097/meg.0b013e328317f4c8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
38 Wolter TR, Wong R, Sarkar SA, Zipris D. DNA microarray analysis for the identification of innate immune pathways implicated in virus-induced autoimmune diabetes. Clin Immunol 2009;132:103-15. [PMID: 19328037 DOI: 10.1016/j.clim.2009.02.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
39 Hashemi N, Rossi S, Navarro VJ, Herrine SK. Safety of peginterferon in the treatment of chronic hepatitis C. Expert Opin Drug Saf. 2008;7:771-781. [PMID: 18983223 DOI: 10.1517/14740330802423291] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
40 Fox AN, Faust TW. Support of Patients During Antiviral Therapy for Hepatitis B and C. Chronic Viral Hepatitis 2009. [DOI: 10.1007/978-1-59745-565-7_13] [Reference Citation Analysis]
41 Zipris D. Innate immunity and its role in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2008;15:326-31. [PMID: 18594272 DOI: 10.1097/MED.0b013e3283073a46] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
42 . Bibliography. Current world literature. Diabetes and the endocrine pancreas II. Curr Opin Endocrinol Diabetes Obes 2008;15:383-93. [PMID: 18594281 DOI: 10.1097/MED.0b013e32830c6b8e] [Reference Citation Analysis]